Provectus announces data from PV-10 Phase 2 study on metastatic melanoma

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.

More... (http://www.news-medical.net/news/20120410/Provectus-announces-data-from-PV-10-Phase-2-study-on-metastatic-melanoma.aspx)